Nanosonics Limited (ASX:NAN)
Australia · Delayed Price · Currency is AUD | Market Cap | 1.05B -14.9% |
| Revenue (ttm) | 207.26M +12.7% |
| Net Income | 20.56M +24.1% |
| EPS | 0.07 +24.7% |
| Shares Out | 294.59M |
| PE Ratio | 53.68 |
| Forward PE | 56.04 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 257,779 |
| Open | 3.540 |
| Previous Close | 3.530 |
| Day's Range | 3.500 - 3.575 |
| 52-Week Range | 2.940 - 4.770 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 4.26 (+19.33%) |
| Earnings Date | Aug 25, 2026 |
About Nanosonics
Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabi... [Read more]
Financial Performance
In fiscal year 2025, Nanosonics's revenue was 198.63 million, an increase of 16.83% compared to the previous year's 170.01 million. Earnings were 20.68 million, an increase of 59.39%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for NAN stock is "Buy." The 12-month stock price target is $4.26, which is an increase of 19.33% from the latest price.
News
Nanosonics Earnings Call Transcript: H1 2026
Revenue grew 9% year-over-year to AUD 102 million, with strong recurring revenue and operating margin expansion. Guidance for 8%-12% revenue growth is reaffirmed, supported by upgrades, new product launches, and disciplined cost management.
Nanosonics Quarterly report: H1 2026
Nanosonics has published its H1 2026 quarterly earnings report on February 23, 2026.
Nanosonics Slides: H1 2026
Nanosonics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 23, 2026.
Nanosonics Earnings release: H1 2026
Nanosonics released its H1 2026 earnings on February 23, 2026, summarizing the period's financial results.
Nanosonics upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital upgraded Nanosonics (NNCSF) to Sector Perform from Underperform with an unchanged price target of A$4. The firm views the shares as fairly valued now that earnings estimates have…
Nanosonics Transcript: AGM 2025
The meeting highlighted strong financial growth, major product launches (trophon3 and CORIS), and a new share buyback. All board and remuneration resolutions passed with high support. Strategic focus remains on innovation, sustainability, and global expansion, with no dividend declared due to low franking credits.
Nanosonics Slides: FY 2025
Nanosonics has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 4, 2025.
Nanosonics downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital downgraded Nanosonics (NNCSF) to Underperform from Sector Perform with a price target of A$4, down from A$4.50. The company’s fiscal 2026 outlook fell significantly below estimates due to…
Nanosonics Earnings Call Transcript: H2 2025
Revenue grew 17% to AUD 198.6 million, with recurring revenue up 20% and profit before tax up 72%. FY 2026 guidance anticipates 8–12% revenue growth, gross margin of 75–77%, and continued investment in innovation, with minimal CORIS revenue expected.
Nanosonics Slides: H2 2025
Nanosonics has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 25, 2025.
Nanosonics Earnings release: H2 2025
Nanosonics released its H2 2025 earnings on August 25, 2025, summarizing the period's financial results.
Nanosonics Annual report: H2 2025
Nanosonics has published its H2 2025 annual report on August 25, 2025.
Nanosonics upgraded to Buy from Hold at Canaccord
Canaccord analyst Elyse Shapiro upgraded Nanosonics (NNCSF) to Buy from Hold with a price target of A$4.74, up from A$4.47. FDA De Novo approval for the company’s Coris device for…
Nanosonics initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Nanosonics with a Sector Perform rating and A$5.25 price target. Nanosonics trophon device offers a unique automated solution for high level disinfection of ultrasoun...